nach oben

Seminars in Immunopathology

Erschienen in:

01.11.2013 | Review

Aryl hydrocarbon receptor and colitis

verfasst von: Ivan Monteleone, Francesco Pallone, Giovanni Monteleone

Erschienen in: Seminars in Immunopathology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

The aryl hydrocarbon receptor (AhR), a transcription factor activated by a large variety of natural and synthetic ligands, has recently become the object of great interest among researchers since it represents an important link between environment and immune-mediated pathologies. In this context, evidence has been accumulated to show that AhR is necessary for the maintenance/expansion of intraepithelial lymphocytes and interleukin-22-producing innate lymphoid cells in the gut and that defects in AhR-delivered signals may contribute to amplify gut tissue destructive immune-inflammatory reactions. We here review the available data supporting the role of AhR in the control of immune homeostasis in the gut and discuss whether and how AhR activators can help dampen inflammatory processes.

Kaser A, Zeissig S, Blumberg RS (2010) Inflammatory bowel disease. Annu Rev Immunol 28:573–621. doi:10.1146/annurev-immunol-030409-101225 PubMedCrossRef

Strober W, Fuss IJ (2011) Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140(6):1756–1767. doi:10.1053/j.gastro.2011.02.016 PubMedCrossRef

MacDonald TT, Monteleone I, Fantini MC, Monteleone G (2011) Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140(6):1768–1775. doi:10.1053/j.gastro.2011.02.047 PubMedCrossRef

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A (2011) Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140(6):1785–1794. doi:10.1053/j.gastro.2011.01.055 PubMedCrossRef

Cosnes J (2004) Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 18(3):481–496. doi:10.1016/j.bpg.2003.12.003 PubMedCrossRef

Hou JK, Abraham B, El-Serag H (2011) Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol 106(4):563–573. doi:10.1038/ajg.2011.44 PubMedCrossRef

Godet PG, May GR, Sutherland LR (1995) Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 37(5):668–673PubMedCrossRef

Gu YZ, Hogenesch JB, Bradfield CA (2000) The PAS superfamily: sensors of environmental and developmental signals. Annu Rev Pharmacol Toxicol 40:519–561. doi:10.1146/annurev.pharmtox.40.1.519 PubMedCrossRef

Denison MS, Nagy SR (2003) Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309–334. doi:10.1146/annurev.pharmtox.43.100901.135828 PubMedCrossRef

10.

Rannug U, Rannug A, Sjoberg U, Li H, Westerholm R, Bergman J (1995) Structure elucidation of two tryptophan-derived, high affinity Ah receptor ligands. Chem Biol 2(12):841–845PubMedCrossRef

11.

Li Y, Innocentin S, Withers DR, Roberts NA, Gallagher AR, Grigorieva EF, Wilhelm C, Veldhoen M (2011) Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147(3):629–640. doi:10.1016/j.cell.2011.09.025 PubMedCrossRef

12.

Cheroutre H, Lambolez F, Mucida D (2011) The light and dark sides of intestinal intraepithelial lymphocytes. Nat Rev Immunol 11(7):445–456. doi:10.1038/nri3007 PubMedCrossRef

13.

Lee JS, Cella M, McDonald KG, Garlanda C, Kennedy GD, Nukaya M, Mantovani A, Kopan R, Bradfield CA, Newberry RD, Colonna M (2011) AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 13(2):144–151. doi:10.1038/ni.2187 PubMedCrossRef

14.

Kiss EA, Vonarbourg C, Kopfmann S, Hobeika E, Finke D, Esser C, Diefenbach A (2011) Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science 334(6062):1561–1565. doi:10.1126/science.1214914 PubMedCrossRef

15.

Spits H, Di Santo JP (2011) The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 12(1):21–27. doi:10.1038/ni.1962 PubMedCrossRef

16.

Alam MS, Maekawa Y, Kitamura A, Tanigaki K, Yoshimoto T, Kishihara K, Yasutomo K (2010) Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. doi:10.1073/pnas.0911755107

17.

Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, Soumelis V (2008) A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 9(6):650–657PubMedCrossRef

18.

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126(6):1121–1133. doi:10.1016/j.cell.2006.07.035 PubMedCrossRef

19.

Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y (2003) Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52(1):65–70PubMedCrossRef

20.

Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204(8):1849–1861PubMedCrossRef

21.

Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S, Jurgens M, Schmechel S, Konrad A, Goke B, Ochsenkuhn T, Muller-Myhsok B, Lohse P, Brand S (2008) Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn’s disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 14(4):437–445. doi:10.1002/ibd.20339 PubMedCrossRef

22.

Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F (1997) Interleukin 12 is expressed and actively released by Crohn’s disease intestinal lamina propria mononuclear cells. Gastroenterology 112(4):1169–1178PubMedCrossRef

23.

Schmidt C, Giese T, Ludwig B, Mueller-Molaian I, Marth T, Zeuzem S, Meuer SC, Stallmach A (2005) Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in ulcerative colitis. Inflamm Bowel Dis 11(1):16–23PubMedCrossRef

24.

Caruso R, Sarra M, Stolfi C, Rizzo A, Fina D, Fantini MC, Pallone F, MacDonald TT, Monteleone G (2009) Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 136(7):2270–2279. doi:10.1053/j.gastro.2009.02.049 PubMedCrossRef

25.

Iliev ID, Spadoni I, Mileti E, Matteoli G, Sonzogni A, Sampietro GM, Foschi D, Caprioli F, Viale G, Rescigno M (2009) Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58(11):1481–1489. doi:10.1136/gut.2008.175166 PubMedCrossRef

26.

Rodriguez-Sosa M, Elizondo G, Lopez-Duran RM, Rivera I, Gonzalez FJ, Vega L (2005) Over-production of IFN-gamma and IL-12 in AhR-null mice. FEBS Lett 579(28):6403–6410. doi:10.1016/j.febslet.2005.10.023 PubMedCrossRef

27.

Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, Stockinger B (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 453(7191):106–109. doi:10.1038/nature06881 PubMedCrossRef

28.

Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, Caccamo M, Oukka M, Weiner HL (2008) Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453(7191):65–71. doi:10.1038/nature06880 PubMedCrossRef

29.

Quintana FJ, Jin H, Burns EJ, Nadeau M, Yeste A, Kumar D, Rangachari M, Zhu C, Xiao S, Seavitt J, Georgopoulos K, Kuchroo VK (2012) Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol 13(8):770–777. doi:10.1038/ni.2363 PubMedCrossRef

30.

Monteleone I, Rizzo A, Sarra M, Sica G, Sileri P, Biancone L, Macdonald TT, Pallone F, Monteleone G (2011) Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 141(1):237–248. doi:10.1053/j.gastro.2011.04.007, e231PubMedCrossRef

31.

Arsenescu R, Arsenescu V, Zhong J, Nasser M, Melinte R, Dingle RW, Swanson H, de Villiers WJ (2011) Role of the xenobiotic receptor in inflammatory bowel disease. Inflamm Bowel Dis 17(5):1149–1162. doi:10.1002/ibd.21463 PubMedCrossRef

32.

Strober W, Fuss IJ, Blumberg RS (2002) The immunology of mucosal models of inflammation. Annu Rev Immunol 20:495–549PubMedCrossRef

33.

Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, Blumberg RS, Xavier RJ, Mizoguchi A (2008) IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 118(2):534–544. doi:10.1172/JCI33194 PubMed

34.

Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA (2008) Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29(6):947–957. doi:10.1016/j.immuni.2008.11.003 PubMedCrossRef

35.

Huang Z, Jiang Y, Yang Y, Shao J, Sun X, Chen J, Dong L, Zhang J (2012) 3,3′-Diindolylmethane alleviates oxazolone-induced colitis through Th2/Th17 suppression and Treg induction. Mol Immunol 53(4):335–344. doi:10.1016/j.molimm.2012.09.007 PubMedCrossRef

36.

Furumatsu K, Nishiumi S, Kawano Y, Ooi M, Yoshie T, Shiomi Y, Kutsumi H, Ashida H, Fujii-Kuriyama Y, Azuma T, Yoshida M (2011) A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci 56(9):2532–2544. doi:10.1007/s10620-011-1643-9 PubMedCrossRef

37.

Takamura T, Harama D, Fukumoto S, Nakamura Y, Shimokawa N, Ishimaru K, Ikegami S, Makino S, Kitamura M, Nakao A (2011) Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis. Immunol Cell Biol 89(7):817–822. doi:10.1038/icb.2010.165 PubMedCrossRef

38.

Perdew GH, Babbs CF (1991) Production of Ah receptor ligands in rat fecal suspensions containing tryptophan or indole-3-carbinol. Nutr Cancer 16(3–4):209–218. doi:10.1080/01635589109514159 PubMedCrossRef

39.

Gandhi R, Kumar D, Burns EJ, Nadeau M, Dake B, Laroni A, Kozoriz D, Weiner HL, Quintana FJ (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11(9):846–853. doi:10.1038/ni.1915 PubMedCrossRef

40.

Singh NP, Singh UP, Singh B, Price RL, Nagarkatti M, Nagarkatti PS (2011) Activation of aryl hydrocarbon receptor (AhR) leads to reciprocal epigenetic regulation of FoxP3 and IL-17 expression and amelioration of experimental colitis. PLoS One 6(8):e23522. doi:10.1371/journal.pone.0023522 PubMedCrossRef

41.

Benson JM, Shepherd DM (2011) Aryl hydrocarbon receptor activation by TCDD reduces inflammation associated with Crohn’s disease. Toxicol Sci 120(1):68–78. doi:10.1093/toxsci/kfq360 PubMedCrossRef

42.

Apetoh L, Quintana FJ, Pot C, Joller N, Xiao S, Kumar D, Burns EJ, Sherr DH, Weiner HL, Kuchroo VK (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11(9):854–861. doi:10.1038/ni.1912 PubMedCrossRef

43.

Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O’Connor W Jr, Murphy AJ, Valenzuela DM, Yancopoulos GD, Booth CJ, Cho JH, Ouyang W, Abraham C, Flavell RA (2012) IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491(7423):259–263. doi:10.1038/nature11535 PubMedCrossRef

Titel: Aryl hydrocarbon receptor and colitis
verfasst von: Ivan Monteleone
Francesco Pallone
Giovanni Monteleone
Publikationsdatum: 01.11.2013
Verlag: Springer Berlin Heidelberg
Erschienen in: Seminars in Immunopathology / Ausgabe 6/2013
Print ISSN: 1863-2297
Elektronische ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-013-0396-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Aryl hydrocarbon receptor and colitis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2013

Role of the aryl hydrocarbon receptor (AhR) in lung inflammation

The role of the aryl hydrocarbon receptor in normal and malignant B cell development

Aryl hydrocarbon receptor and experimental autoimmune arthritis

New insights into the aryl hydrocarbon receptor as a modulator of host responses to infection

Aryl hydrocarbon receptor promotes RORγt+ Group 3 ILCs and controls intestinal immunity and inflammation

Functions of the aryl hydrocarbon receptor in the skin

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin